Glifonap2.5 mgF.C.Tablets

A novel sodium glucose cotransporter 2 inhibitor for type 2 diabetes mellitus (T2DM) treatment.

Each film coated tablet contains: Luseogliflozin 2.5 mg.

  • Luseogliflozin: is a drug with a new mechanism of action that selectively inhibits sodium glucose cotransporter-2 (SGLT2). It lowers blood glucose levels by inhibiting reabsorption of glucose in the proximal renal tubules with an increase in urinary glucose excretion.
  • The clinical trials have confirmed the blood glucose lowering effect of Luseogliflozin on HbA1c, either on both monotherapy or in combination with other oral hypoglycemic agents.
  • Luseogliflozin: also showed favourable pharmacokinetic and pharmacodynamic profiles, supporting the feasibility of once daily administration regimen. 
  • Luseogliflozin: has improved insulin sensitivity in liver & peripheral tissues and also improved cell functionwitha reduction of overall caloric load with a significatn body weight reduction.
  • Luseogliflozin: shows well tolerability with low incidence of adverse effects so can be used for long term treatment without safety issues as it has a different mechanisms of action than traditional oral hypoglycemic agents.
  • Luseogliflozin: can be administered in combination with a broad range of other drugs.
Dosage & Administration:
  • Luseogliflozin: shows good tolerability and safety either in a single dose or for 7 days multiple dose study in healthy subjects.
  • Monotherapy with 1-10 mg Luseogliflozin for 12 weeks significantly improved glycemic control.